TY  - GEN
AU  - Han,Boram
AU  - Jung,Joo Young
AU  - Kim,Hyeong Su
AU  - Cho,Ji Woong
AU  - Kim,Kab Choong
AU  - Lim,Hyun
AU  - Kang,Ho Suk
AU  - Ha,Hong Il
AU  - Kim,Min-Jeong
AU  - Kim,Jung Hoon
AU  - Choi,Dae Ro
AU  - Jang,Geundoo
AU  - Kim,Jung Han
AU  - Song,Hunho
AU  - Zang,Dae Young
TI  - A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer
SN  - 1432-0843
PY  - 2017///0526
KW  - Administration, Intravenous
KW  - Adult
KW  - Aged
KW  - Antimetabolites, Antineoplastic
KW  - administration & dosage
KW  - Antineoplastic Agents
KW  - Antineoplastic Agents, Phytogenic
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Camptothecin
KW  - Dose-Response Relationship, Drug
KW  - Drug Combinations
KW  - Female
KW  - Gastrointestinal Neoplasms
KW  - drug therapy
KW  - Humans
KW  - Irinotecan
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Organoplatinum Compounds
KW  - Oxaliplatin
KW  - Oxonic Acid
KW  - Tegafur
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1007/s00280-016-3147-y
ER  -